Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Vascular Stability, Angiogenesis, and Ophthalmic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Tie2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Tie2 ECD-Fc / Mutant Protein (HEK293 Expressed) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Native glycosylation. |
View Tie2 Products |
| Gene Delivery | Tie2 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell lines. Native conformation preserved. |
View Tie2 Products |
| Benchmark Ab | Anti-Tie2 Recombinant Antibody (Positive Control) Sequence-verified benchmark for binding and blockade assays. |
View Tie2 Products |
| Validator | Tie2 siRNA Set Sequence-verified siRNA for knockdown verification and specificity controls. |
View Tie2 Products |
| Related Target A | ANGPT1 (Angiopoietin-1) Primary natural agonist for Tie2, crucial for vascular stability. |
View ANGPT1 Products |
| Related Target B | ANGPT2 (Angiopoietin-2) Context-dependent antagonist; target for combination ophthalmic therapies. |
View ANGPT2 Products |
| Related Target C | VEGFA Synergistic pathway in angiogenesis and retinal vascular diseases. |
View VEGFA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation & ligand competition | Human/Mouse/Cyno Tie2 ECD-Fc ortholog panel; >95% purity; Sequence Verified; Native glycosylation (HEK293). |
| Receptor clustering and activation (agonistic mAb screening) | Oligomeric structures mimicking natural presentation; Theoretical MW verified. |
| Subfamily kinase selectivity (TKI development) | Homolog panel proteins strictly verified by mass spec for off-target screening. |
| Lack of conformation-specific controls & false positives | Tie2 Lentivirus for stable full-length cell lines; siRNA set for knockdown validation. |
Live Tie2 (TEK/CD202b) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Tie2 therapeutics is intensifying, with major players shifting focus from traditional monospecific antibodies to bispecific modalities targeting both Ang2 and VEGF pathways, as exemplified by Roche's Faricimab. Beyond ophthalmology, the next wave of R&D is targeting direct Tie2 agonism to restore vascular stability in oncology, severe inflammatory conditions, and systemic vascular leakage diseases. Subcutaneous delivery platforms are also emerging to improve patient convenience.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific mAb (Ang2/VEGF) | Roche, Regeneron | Ophthalmology (nAMD, DME, DR) | Binding kinetics & Heterodimer Validation (Need High-Purity ECD) |
| Agonistic mAbs / Peptides | Aerpio, Hanmi | Diabetic Retinopathy, Vascular Leakage | Clustering Assays (Need HEK293 Expressed Antigens) |
| Small Molecules (VE-PTP inhibitors) | Aerpio (AKB-9778) | Glaucoma, Diabetic Complications | Selectivity Assay (Need Kinase Domain Proteins) |
| Anti-Ang2 Monoclonal | Regeneron (investigational) | Oncology, Ophthalmology | Ligand blockade competition assay (High-purity Tie2 ECD-Fc) |